Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus reuteri DSM 17938

What does the research say about Lactobacillus reuteri DSM 17938?

8 health outcomes synthesised

Lactobacillus reuteri DSM 17938 has been studied across 8 health outcomes, with the strongest evidence supporting its use for reducing diarrhea rate in children (11 papers), reduced crying time in infants with colic (9 papers), and reduced abdominal pain (13 papers). Typical effective doses range from 1×10^8 to 5×10^8 CFU/day in pediatric populations, with most studies in infants and children.

Strongest Evidence

  • Reduced Diarrhea Rate (high evidence, 11 papers): 8 of 11 studies found benefits in children with acute gastroenteritis or in daycare, with doses around 1–4×10^8 CFU/day over short periods.
  • Reduced Crying Time (high evidence, 9 papers): 8 of 9 studies reported benefits in infants with colic, particularly breastfed infants, with moderate-to-large reductions (-45 to -65 minutes/day) at doses of 1–5×10^8 CFU/day over 28 days.
  • Reduced Abdominal Pain (moderate evidence, 13 papers): 11 of 13 studies found small-to-moderate benefits in children with functional abdominal pain or colic, at 10^8 CFU/day over 8 weeks.
  • Reduced Duration of Diarrhea (moderate evidence, 5 papers): All 5 studies reported benefits in children, with doses around 10^8 CFU/day.
  • Reduced Vomiting Frequency (moderate evidence, 3 papers): All 3 studies found small benefits in healthy and breastfed infants, dose 10^8 CFU/day for 4 weeks.

Mixed or Weaker Evidence

  • Reduced Crying Duration (low evidence, 3 papers): 2 of 3 studies found benefits in infants with colic, but one large RCT in antibiotic-exposed neonates found no effect.
  • Reduced Diarrhea (low evidence, 3 papers): Only 1 of 3 studies showed benefit, in hospitalized children; 2 neutral in healthy settings.
  • Reduced Stool Volume (very low evidence, 3 papers): 1 of 3 studies showed benefit in children with functional constipation.

Effective Dose Patterns

  • The most consistent dose across multiple outcomes (abdominal pain, diarrhea duration, vomiting) is 10^8 CFU/day.
  • For diarrhea rate and crying time, doses up to 5×10^8 CFU/day are also effective.
  • No dose was consistently effective for weaker outcomes.

Population Insights

  • Children dominate most studies: For diarrhea, abdominal pain, and infant colic, populations include children 4–18 years, infants, and preterm infants.
  • Breastfed infants show particular benefit for crying time and vomiting reduction.
  • Hospitalized or antibiotic-exposed children may have diminished benefit for some outcomes.

Notable Caveats

  • Publication bias possible: Across 8 syntheses, the caveat notes that null results may be underreported.
  • Evidence strength varies wildly: From very low (stool volume, 1/3 positive) to high (diarrhea rate, 8/11 positive).
  • Short study durations: Most studies lasted under 8 weeks, and for diarrhea, often just 5 days.
  • Small sample sizes: Many studies were moderate or small, especially for weaker outcomes.

Frequently asked

  • What is Lactobacillus reuteri DSM 17938 good for according to research?
    Research shows it is most consistently beneficial for reducing diarrhea rate in children (8 of 11 studies), reducing crying time in infants with colic (8 of 9 studies), and reducing abdominal pain in children (11 of 13 studies). Benefits are also seen for reducing diarrhea duration and vomiting frequency, but evidence is weaker for crying duration and stool volume.
  • What dose of Lactobacillus reuteri DSM 17938 is typically used in studies?
    The most common effective dose across multiple outcomes is 10^8 CFU/day. For diarrhea rate and crying time, doses up to 1–5×10^8 CFU/day (1 to 5 billion colony-forming units) are also used. Studies typically administer it once daily.
  • Who benefits most from Lactobacillus reuteri DSM 17938?
    The strongest evidence is in infants with colic (especially breastfed infants) and children with acute gastroenteritis, functional abdominal pain, or attending daycare. For crying time, the effect is largest in breastfed infants. For diarrhea, results are clearest in children aged 6–36 months with acute diarrhea.
  • Are there caveats or limitations in the research on Lactobacillus reuteri DSM 17938?
    Yes. Many syntheses flag possible publication bias, meaning null results may be underreported. Several outcomes have small numbers of studies (3–5 papers) and study durations are short (often 5–56 days). Some larger or recent trials found no effect, suggesting benefits may be context-dependent.
  • Does Lactobacillus reuteri DSM 17938 help with abdominal pain?
    Evidence is moderate: 11 of 13 studies found small-to-moderate benefits, primarily in children with functional abdominal pain or colic. The typical dose is 10^8 CFU/day over 8 weeks. However, two neutral studies suggest the effect may be inconsistent.
  • Is there evidence for Lactobacillus reuteri DSM 17938 reducing crying duration?
    The evidence is weak and mixed. Of 3 studies, only 2 reported benefits, with effect sizes varying from small to large. One large review found a large benefit in colicky infants, but a recent RCT in antibiotic-exposed neonates found no effect. Use is supported only in infants with colic.

Safety profile

25 studies reporting safety data2 serious adverse events

Across 25 clinical studies, no specific adverse events were found to be increased with Lactobacillus reuteri DSM 17938 compared to control. In 18 studies, no significant differences were observed for events such as crying time, spitting-up, colic, and gastrointestinal symptoms, with some outcomes favoring the probiotic. The supplement was described as well tolerated in 26 mentions, and serious adverse events were not attributed to the probiotic. Overall, the evidence indicates a favorable safety profile in the studied populations, primarily infants and children.

Caveats: Most studies were short-term (typically ≤8 weeks) and focused on infant populations; long-term safety and effects in adults or immunocompromised individuals are not well characterized. Many trials were powered for efficacy rather than safety, so rare adverse events may not have been detected.

Most-studied combinations with Lactobacillus reuteri DSM 17938

most supplement research is combination research
  • Gastrus For Optimal Gut Health

    By BioGaia

    4.7 (2.4K reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $24.00
    In
    Vitacost
    $-
    Out
    Vitamin Shoppe
    $-
    Out
  • Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $26.99
    In
    Vitacost
    $26.99
    In
    Vitamin Shoppe
    $-
    Out
  • Prodentis Kids

    By BioGaia

    4.6 (479 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $23.00
    In
    Vitacost
    $23.99
    In
    Vitamin Shoppe
    $-
    Out
  • Prodentis For Gums And Teeth

    By BioGaia

    4.8 (103 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $23.00
    In
    Vitacost
    $-
    Out
    Vitamin Shoppe
    $-
    Out
  • Protectis MUM

    By BioGaia

    4.7 (172 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $22.99
    In
    Vitacost
    $-
    Out
    Vitamin Shoppe
    $-
    Out
  • Prodentis For Gums And Teeth

    By BioGaia

    4.6 (1.8K reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    Out
    iHerb
    $23.00
    In
    Vitacost
    $-
    Out
    Vitamin Shoppe
    $-
    Out
Back to top